Last mentioned: 3d ago
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies.
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages.
Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.